Coexisting autoimmune pancreatitis and pancreatic adenocarcinoma: Diagnostic challenges and case insights Authors: Hind Qajia, Chaimaa Jabbari, Saleck Choumad, Maryam Lejouad, Yassine Eddahoumi, Ittimade Nassar, Kaoutar Imrani Published: 2026 ABSTRACT AbstractThe coexistence of autoimmune pancreatitis and pancreatic adenocarcinoma represents a rare but clinically significant diagnostic dilemma. Elevated IgG4 levels and imaging features suggestive of autoimmune pancreatitis may mask an underlying malignancy, leading to potential delays in definitive diagnosis and treatment. This overlap highlights the limitations of relying solely on clinical, serologic, and radiologic findings in the absence of histopathologic confirmation. We report a case of pancreatic ductal adenocarcinoma occurring in the setting of suspected autoimmune pancreatitis (AIP), highlighting the diagnostic challenge of overlapping imaging and biochemical features and the potential coexistence of both entities. A 51-year-old patient presented with progressive jaundice and unintentional weight loss. Laboratory evaluation revealed cholestasis, elevated tumor markers including CA 19-9, and markedly increased serum IgG4 levels (340 mg/dL; reference range 4.8-105 mg/dL). Contrast-enhanced computed tomography revealed a diffusely enlarged, sausage-shaped pancreas, associated with a focal hypoattenuating lesion in the uncinate process, regional lymphadenopathy, and peritoneal nodularity with ascites. Assessment of the pancreatic ductal system using gadolinium-enhanced MRI and MRCP demonstrated irregular narrowing of the main pancreatic duct without significant upstream dilatation. Histopathologic examination confirmed pancreatic ductal adenocarcinoma. This case emphasizes that pancreatic malignancy may coexist with AIP, and should not be excluded despite characteristic imaging and biochemical findings.Keywords: Pancreatic adenocarcinoma, Autoimmune pancreatitis, IgG4 Introduction Autoimmune pancreatitis (AIP) is a distinct form of chronic pancreatitis characterized by specific imaging features, including diffuse or focal pancreatic enlargement and irregular narrowing of the main pancreatic duct without significant upstream dilatation, as demonstrated on ultrasonography, computed tomography, and/or magnetic resonance imaging, in association with narrowing of the main pancreatic duct on endoscopic retrograde cholangiopancreatography. Laboratory findings typically include elevated serum markers, most notably increased IgG4 levels, and histopathologic features consist of a mixed inflammatory infiltrate predominantly involving the pancreatic ducts, accompanied by fibrotic changes consistent with sclerosing pancreatitis [1]. Differentiating AIP from pancreatic carcinoma is of paramount importance, not only because of overlapping features, but also because both entities may coexist. As these 2 entities may present with overlapping clinical and imaging features [2,3]. Several recent reports have described cases of AIP that closely mimic pancreatic malignancy [4,5]. In this report, we describe a case of pancreatic adenocarcinoma associated with autoimmune pancreatitis. A key diagnostic pitfall is not only that AIP may mimic malignancy, but that pancreatic adenocarcinoma may be present despite imaging features suggestive of AIP. Typical imaging features favoring pancreatic adenocarcinoma include: •Focal hypoattenuating mass. Focal hypoattenuating mass. •Distal pancreatic duct dilatation. Distal pancreatic duct dilatation. •Upstream pancreatic atrophy. Upstream pancreatic atrophy. Case report A 51-year-old patient with no significant past medical history presented with progressive mucocutaneous jaundice evolving over a 2-month period, associated with general health deterioration, including asthenia and weight loss of approximately 8 kg. There was no family history of pancreatic cancer. On clinical examination, the patient was icteric, with jaundice involving the skin and sclerae. Abdominal examination revealed no palpable mass, hepatomegaly, or splenomegaly, and there were no signs of abdominal tenderness or ascites. Laboratory investigations demonstrated: •Total bilirubin: 148 µmol/L (reference: 3-20 µmol/L) Total bilirubin: 148 µmol/L (reference: 3-20 µmol/L) •Direct bilirubin: 112 µmol/L (reference: <5 µmol/L) Direct bilirubin: 112 µmol/L (reference: <5 µmol/L) •ALP: 420 U/L (reference: 40-130 U/L) ALP: 420 U/L (reference: 40-130 U/L) •GGT: 380 U/L (reference: <60 U/L) GGT: 380 U/L (reference: <60 U/L) •Lipase: 180 U/L (reference: 13-60 U/L) Lipase: 180 U/L (reference: 13-60 U/L) •CA 19-9: 680 U/mL (reference: <37 U/mL) CA 19-9: 680 U/mL (reference: <37 U/mL) •Serum IgG4: 340 mg/dL (reference: 4.8-105 mg/dL) Serum IgG4: 340 mg/dL (reference: 4.8-105 mg/dL) Abdominal ultrasonography performed as an initial imaging modality demonstrated diffuse enlargement of the pancreas with heterogeneous echotexture, along with mild intrahepatic bile duct dilatation, raising suspicion for an underlying pancreatic pathology Fig. 1. Contrast-enhanced axial CT images demonstrating a pancreatic uncinate process mass (red arrow), diffuse sausage-shaped pancreatic enlargement, left perirenal infiltration (blue arrow), associated lymphadenopathy, a dilatation of the intrahepatic bile ducts (green arrow), and peritoneal effusion. Contrast-enhanced computed tomography (pancreatic protocol) revealed: •Diffuse pancreatic enlargement with a sausage-shaped morphology. Diffuse pancreatic enlargement with a sausage-shaped morphology. •A poorly defined hypoattenuating lesion in the uncinate process measuring approximately 28 mm. A poorly defined hypoattenuating lesion in the uncinate process measuring approximately 28 mm. •No significant upstream pancreatic duct dilatation. No significant upstream pancreatic duct dilatation. •No pancreatic calcifications. No pancreatic calcifications. •Homogeneous appearance without necrosis or cystic change. Homogeneous appearance without necrosis or cystic change. Associated findings included: •Regional lymphadenopathy. Regional lymphadenopathy. •Peritoneal nodularity consistent with peritoneal carcinomatosis. Peritoneal nodularity consistent with peritoneal carcinomatosis. •Moderate ascites (free intraperitoneal fluid). Moderate ascites (free intraperitoneal fluid). Magnetic resonance imaging (gadolinium-enhanced MRI with MRCP) demonstrated: •Diffuse pancreatic enlargement with delayed enhancement Diffuse pancreatic enlargement with delayed enhancement •A focal lesion in the uncinate process showing diffusion restriction and relative hypoenhancement A focal lesion in the uncinate process showing diffusion restriction and relative hypoenhancement •Irregular narrowing of the main pancreatic duct without upstream dilatation Irregular narrowing of the main pancreatic duct without upstream dilatation •Long-segment ductal narrowing in the pancreatic body Long-segment ductal narrowing in the pancreatic body •A long, smooth stricture of the common bile duct A long, smooth stricture of the common bile duct The previously described “renal-shaped appearance” corresponded to renal involvement suggestive of IgG4-related disease with perirenal infiltration Fig. 2. Diffusion-weighted imaging (A), Contrast-enhanced MRI (B), and MR cholangiopancreatography (C) showing a pancreatic uncinate process lesion (red arrow) associated with a sausage-shaped pancreas, left perirenal infiltration (blue arrow), filiform stenosis of the common bile duct (green arrow), and irregularity of the main pancreatic duct. Given the presence of peritoneal nodularity suggestive of metastatic disease, malignancy was strongly suspected despite features suggestive of AIP. An image-guided percutaneous biopsy of the pancreatic lesion was performed, rather than peritoneal biopsy, due to higher diagnostic yield and accessibility. Histopathological analysis confirmed pancreatic ductal adenocarcinoma with associated fibrotic changes. The patient was referred to the oncology department and received palliative chemotherapy due to locally advanced disease with peritoneal metastases. Clinical follow-up over 3 months showed partial improvement of jaundice after biliary stenting and stabilization of general condition under treatment. Discussion Autoimmune pancreatitis (AIP) is a rare clinical entity. Its diagnosis relies on a combination of clinical presentation, radiologic findings, serologic markers, and histopathologic features. In most cases, classical risk factors for chronic pancreatitis, such as alcohol use, are absent [1]. Clinically, AIP may present with acute epigastric pain, progressive weight loss, and mucocutaneous jaundice [2]. Beyond mimicking pancreatic ductal adenocarcinoma, AIP may also coexist with malignancy, representing a critical diagnostic pitfall. This overlap creates a high-stakes clinical scenario in which the risk of missing a life-threatening cancer must be weighed against the avoidance of unnecessary surgery, particularly given the well-documented responsiveness of AIP to corticosteroid therapy. AIP is classified into 2 types. Type 1 AIP corresponds to IgG4-related sclerosing disease, which predominantly affects men over 50-60 years of age. Histologically, it is characterized by dense periductal lymphoplasmacytic infiltration, pancreatic fibrosis, and obliterative venulitis. Serum IgG4 levels are typically markedly elevated, and multiorgan involvement, particularly affecting the biliary tract, is common. Type 2 AIP is more frequently observed in patients around 40 years of age and is often associated with other autoimmune disorders, including sclerosing cholangitis, chronic inflammatory bowel disease, Sjögren’s syndrome, thyroiditis, diabetes mellitus, and retroperitoneal fibrosis. In Type 2 AIP, serum immunoglobulin levels are generally normal [3]. Several serologic markers have been described in autoimmune pancreatitis (AIP), including rheumatoid factor, antinuclear antibodies (ANA), anticarbonic anhydrase II antibodies, and antilactoferrin antibodies. Among these, serum IgG4 measurement remains the most sensitive and specific marker, with levels exceeding 1.35 g/L or more than twice the upper limit of normal. However, these markers have limited negative predictive value, and their absence does not exclude the diagnosis when there is a strong clinical and radiologic suspicion [4]. Imaging findings in AIP reflect both parenchymal and ductal alterations. The pancreas typically appears swollen and delobulated, demonstrating hypodensity on computed tomography and hypointensity on T1-weighted magnetic resonance imaging, with delayed enhancement following contrast administration. A fibrous halo may be observed surrounding any focal mass-like area, while calcifications and pseudocysts are uncommon. Ductal abnormalities are best evaluated using magnetic resonance cholangiopancreatography, which characteristically demonstrates multiple skipped narrowings (“skip lesions”) of the main pancreatic duct without upstream dilatation [5]. The morphology of ductal stenosis can aid in distinguishing AIP from other pancreatic diseases. The main pancreatic duct often appears threadlike and irregular, with stepped strictures that are centrally located and not associated with upstream dilatation, as was clearly demonstrated on the cholangiopancreatography MRI performed in our patient. Because autoimmune pancreatitis (AIP) can closely mimic pancreatic ductal adenocarcinoma and its diagnosis is increasingly recognized, it may pose a significant diagnostic and therapeutic challenge. Clinicians must carefully balance the potential risk of missing a life-threatening malignancy against the need for symptom control and the desire to avoid unnecessary surgical intervention. These considerations are particularly relevant given that many cases of AIP respond effectively to corticosteroid therapy. Several diagnostic frameworks have been proposed to help distinguish AIP from pancreatic adenocarcinoma, incorporating imaging features, laboratory data, and histopathologic findings [6]. Nonetheless, these criteria are not definitive and would not have allowed an accurate preoperative diagnosis in our patient. The coexistence of autoimmune pancreatitis (AIP) and pancreatic adenocarcinoma poses a diagnostic challenge, as both conditions can share clinical and radiological features such as jaundice, weight loss, and diffuse pancreatic enlargement [7,8]. Although some cases report synchronous or metachronous associations, current literature does not demonstrate that AIP is an independent risk factor for pancreatic cancer [[9], [10], [11]]. Our observation illustrates this rare association, highlighting the importance of histopathologic confirmation even when imaging and serologic markers suggest AIP. Management consisted of palliative chemotherapy, with partial improvement of jaundice after biliary stenting and stabilization of the patient’s general condition, underscoring the value of a multimodal approach in the care of these patients. Prior to this report, Inoue [12] described a single case of pancreatic adenocarcinoma coexisting with AIP. In the previously reported case, the diagnosis of pancreatic carcinoma was established based on pancreatic duct brushings, without surgical resection, in a patient who had lung and bone metastases. The diagnosis of autoimmune pancreatitis (AIP) was not confirmed histologically and was based solely on diffuse pancreatic enlargement in combination with elevated serum IgG4 levels. Kamisawa et al. [13] described a 74-year-old patient with markedly elevated serum IgG4 who underwent pancreaticoduodenectomy and was found to have pancreatic ductal adenocarcinoma accompanied by lymphoplasmacytic infiltration of the biliary tree and duodenum [14]. Although in this patient the IgG4-related inflammatory disease did not involve the pancreas itself, the case underscores the issue highlighted by our report: the presence of IgG4-related inflammatory disease does not exclude the possibility of synchronous pancreatic malignancy Table 1. Table 1Comparative table of reported cases in the literature: Clinical and radiological data.Table 1 – dummy alt textFeaturePresent caseInoue et al. [3]Kamisawa et al. [7]Age/sex51/not specifiedNot specified74/maleClinical presentationJaundice, unintentional weight loss (8 kg)JaundiceJaundiceSerum IgG4Elevated (340 mg/dL)ElevatedMarkedly elevatedCA 19-9Elevated (680 U/mL)ElevatedNot specifiedPancreatic morphologyDiffuse enlargement (“sausage-shaped”)Diffuse enlargementNot specifiedFocal pancreatic lesionYes (uncinate process, 28 mm)No clear massYesMain pancreatic ductIrregular narrowing without upstream dilatationNot specifiedNot specifiedExtrapancreatic involvementPeritoneal carcinomatosis, renal involvementLung and bone metastasesIgG4-related biliary involvementImaging suspicion of AIPYesYesPartialHistologic confirmation of AIPPartial (fibrotic/inflammatory changes)NoNo (extrapancreatic IgG4 disease)Diagnosis of adenocarcinomaBiopsy-confirmedCytology (duct brushing)Surgical specimenManagementPercutaneous biopsyNonsurgicalPancreaticoduodenectomyKey messageCoexistence of AIP and malignancyPossible coexistenceIgG4 disease does not exclude cancer Comparative table of reported cases in the literature: Clinical and radiological data. This case serves as a cautionary example in the management of patients suspected of having AIP. For patients who fully satisfy established diagnostic criteria for AIP, a trial of steroid therapy may be appropriate. However, in patients who only partially meet these criteria or whose imaging abnormalities fail to resolve promptly during treatment, surgical resection should be carefully considered to avoid missing an underlying malignancy. Conclusion The diagnosis of autoimmune pancreatitis (AIP) relies on a combination of clinical, laboratory, and radiologic findings. AIP should be considered in patients presenting with a pancreatic mass without features strongly suggestive of pancreatic adenocarcinoma, in order to avoid unnecessary pancreatic resection. When uncertainty persists between AIP and malignancy, a trial of corticosteroid therapy with careful monitoring of clinical and radiologic response may be warranted. This case does not represent unnecessary surgery, but rather highlights the risk of missing malignancy in patients with suspected AIP. Pancreatic adenocarcinoma may coexist with autoimmune pancreatitis, and characteristic imaging or biochemical features of AIP should not preclude thorough evaluation for malignancy. Patient consent Written informed consent was obtained from the patient for the publication of this case report. Footnotes Competing Interests: The authors have declared that no competing interests exist. References